HIV antiretroviral therapy — Competitive Intelligence Brief

HIV antiretroviral therapy (HIV antiretroviral therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy. Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy Infectious Disease / Virology Small molecule

Target snapshot

HIV antiretroviral therapy (HIV antiretroviral therapy) — French National Agency for Research on AIDS and Viral Hepatitis. HIV antiretroviral therapy works by inhibiting viral replication through multiple mechanisms targeting different stages of the HIV life cycle.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HIV antiretroviral therapy TARGET	HIV antiretroviral therapy	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Antiretroviral combination therapy
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
Atazanavir + Ritonavir + 2 NRTIs	Atazanavir + Ritonavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
Switch to DRV/cobicistat + 3TC	Switch to DRV/cobicistat + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitor)	HIV protease, CYP3A4, HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Chang Gung Memorial Hospital · 1 drug in this class
3. Danish HIV Research Group · 1 drug in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Hospital Nossa Senhora da Conceicao · 1 drug in this class
6. Kristine Patterson, MD · 1 drug in this class
7. PETHEMA Foundation · 1 drug in this class
8. University of Alberta · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class